Too much vitamin B6 can be toxic. 3 symptoms to watch out for
In an ABC report earlier this week, a spokesperson for the Therapeutic Goods Administration (TGA) says it may have underestimated the extent of the side effects from vitamin B6 supplements.
However, there are proposals to limit sales of high-dose versions due to safety concerns.
A pathologist who runs a clinic that tests vitamin B6 in blood samples from across Australia also appeared on the program. He told the ABC that data from May suggests 4.5% of samples tested had returned results 'very likely' indicating nerve damage.
So what are vitamin B6 supplements? How can they be toxic? And which symptoms do you need to watch out for?
Vitamin B6, also known as pyridoxine, plays an important role in keeping the body healthy. It is involved in the metabolism of proteins, carbohydrates and fats in food. It is also important for the production of neurotransmitters – chemical messengers in the brain that maintain its function and regulate your mood.
Vitamin B6 also supports the immune system by helping to make antibodies, which fight off infections. And it is needed to produce haemoglobin, the protein in red blood cells that carries oxygen around the body.
Some women take a vitamin B6 supplement when pregnant. It is thought this helps reduce the nausea associated with the early stages of pregnancy. Some women also take it to help with premenstrual syndrome.
However, most people don't need, and won't benefit from, a vitamin B6 supplement. That's because you get enough vitamin B6 from your diet through meat, breakfast cereal, fruit and vegetables.
You don't need much. A dose of 1.3–1.7 milligrams a day is enough for most adults.
Currently, vitamin B6 supplements with a daily dose of 5–200mg can be sold over the counter at health food stores, supermarkets and pharmacies.
Because of safety concerns, the TGA is proposing limiting their sale to pharmacies, and only after consultation with a pharmacist.
Daily doses higher than 200mg already need a doctor's prescription. So under the proposal that would stay the same.
If you take too much vitamin B6, in most cases the excess will be excreted in your urine and most people won't experience side effects. But there is a growing concern about long-time, high-dose use.
A side effect the medical community is worried about is peripheral neuropathy – where there is damage to the nerves outside the brain and spinal cord. This results in pain, numbness or weakness, usually in your hands and feet. We don't yet know exactly how this happens.
In most reported cases, these symptoms disappear once you stop taking the supplement. But for some people it may take three months to two years before they feel completely better.
There is growing, but sometimes contradictory, evidence that high doses (more than 50mg a day) for extended periods can result in serious side effects.
A study from the 1990s followed 70 patients for five years who took a dose of 100 to 150mg a day. There were no reported cases of neuropathy.
But more recent studies show high rates of side effects.
A 2023 case report provides details of a man who was taking multiple supplements. This resulted in a daily combined 95mg dose of vitamin B6, and he experienced neuropathy.
Another report describes seven cases of neuropathy linked to drinking energy drinks containing vitamin B6.
Reports to the TGA's database of adverse events notifications (a record of reported side effects) shows 174 cases of neuropathy linked with vitamin B6 use since 2023.
The current advice is that someone who takes a dose of 50mg a day or more, for more than six months, should be monitored by a health-care professional. So if you regularly take vitamin B6 supplements you should discuss continued use with your doctor or pharmacist.
There are three side effects to watch out for, the first two related to neuropathy:
numbness or pain in the feet and hands
difficulty with balance and coordination as a result of muscle weakness
heartburn and nausea.
If you have worrying side effects after taking vitamin B6 supplements, contact your state's poison information centre on 13 11 26 for advice.
This article is republished from The Conversation. It was written by: Nial Wheate, Macquarie University and Slade Matthews, University of Sydney
Read more:
Does eating cheese before bed really give you nightmares? Here's what the science says
How should I talk to my kids about abuse and body safety?
Lung cancer screening hopes to save lives. But we also need to watch for possible harms
Nial Wheate in the past has received funding from the ACT Cancer Council, Tenovus Scotland, Medical Research Scotland, Scottish Crucible, and the Scottish Universities Life Sciences Alliance. He is a fellow of the Royal Australian Chemical Institute. Nial is the chief scientific officer of Vaihea Skincare LLC, a director of SetDose Pty Ltd (a medical device company) and was previously a Standards Australia panel member for sunscreen agents. He is a member of the Haleon Australia Pty Ltd Pain Advisory Board. Nial regularly consults to industry on issues to do with medicine risk assessments, manufacturing, design and testing.
Slade Matthews provides scientific evaluations to the Therapeutic Goods Administration as a member of the Therapeutic Goods Assessment and Advisory Panel. Slade serves on the NSW Poisons Advisory Committee for NSW Health as the minister-nominated pharmacologist appointed by the Governor of NSW.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
The best states to have a baby in 2025 (and the 10 that need to do better)
If you're expecting a baby, where you live can make a big difference in everything from how much you'll pay for delivery to the quality of care your newborn receives. According to WalletHub's just-released 2025 Best & Worst States to Have a Baby report, the average cost of a conventional birth is more than $2,600 for mothers with insurance and nearly $15,000 for those without. For many parents, the financial and logistical realities of birth are prompting a bigger question: What does 'baby-friendly' actually look like when you're the one giving birth? WalletHub analyzed all 50 states and the District of Columbia across 31 factors, including hospital delivery costs, infant care expenses, healthcare access, and the number of pediatricians per capita. The results highlight how different the experience of welcoming a child can be depending on your zip code. The 10 best states to have a baby in 2025 Massachusetts North Dakota Minnesota New Hampshire Maine Rhode Island Vermont Washington Iowa District of Columbia Why Massachusetts leads the list Massachusetts has the third-lowest infant mortality rate, the eighth-lowest maternal mortality rate, and strong parental leave policies. It also ranks high in childhood vaccination rates and food security. For new parents, that translates to better infrastructure, more accessible care, and policy-level support during one of life's most demanding transitions. Related: Where to give birth: Here are your labor and delivery options The 10 hardest states to give birth in While some states are building strong foundations for new parents, others leave families facing significant hurdles from the very start. According to WalletHub's analysis, these are the 10 lowest-ranked states when it comes to birth-related cost, healthcare access, and family support: 42. West Virginia 43. Oklahoma 44. Florida 45. Arkansas 46. New Mexico 47. Georgia 48. South Carolina 49. Nevada 50. Alabama 51. Mississippi Parents in these states often face higher rates of low birth weight, fewer OB-GYNs per capita, and little to no paid leave, all of which can increase stress during pregnancy and postpartum. Why Mississippi leads the list In Mississippi, for example, families navigate some of the highest risks and fewest resources in the country. Consistently limited access to care and support leaves many new parents without the tools they need to feel safe and prepared. Your state can shape your experience—long before and long after delivery The report revealed dramatic differences across the country: South Dakota has the lowest average annual cost for early child care—3.5 times lower than in D.C., which has the highest. That kind of gap can determine whether a parent returns to work out of choice or financial necessity, and whether care is chosen based on quality or affordability. District of Columbia has the most midwives and OB-GYNs per capita. More access means less time on waitlists, more flexibility in choosing providers, and a higher chance of being seen when it matters most. Massachusetts leads the nation in parental leave policies. These gaps reflect what many parents already know firsthand: the support you need to raise a child depends heavily on where you live. Related: The United States is the most expensive country to give birth in What parents can do—no matter where they live If you're in a state that ranks lower on WalletHub's list, it doesn't mean you're out of options. Experts recommend: Tapping into community resources: Local nonprofits and parent networks can help bridge the gap in childcare and healthcare access. Advocating for policy change: From zoning laws to parental leave policies, many of the solutions start at the local level. Leaning on support systems: Building your own 'village,' whether through friends, family, or community groups, is critical for both parents and babies. Because whether you live in Massachusetts or Mississippi, one thing is clear: parents shouldn't have to navigate this alone. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Former X CEO Linda Yaccarino named top exec of weight-loss company
Linda Yaccarino, the former X CEO who left the social media company last month in the wake of yet another Elon Musk controversy, has been named the top executive at health company eMed. eMed Population Health provides support for patients on GLP-1 medications, such as Wegovy and Ozempic, that treat diabetes and obesity. 'Our mission is revolutionizing how people receive safe, effective care for chronic condition management through GLP-1 therapies, while building the programs and technologies needed to sustain lasting health outcomes,' Yaccarino wrote in a post on Tuesday announcing her new role as CEO. 'This is truly a transformational moment in preventative healthcare, and I'm energized by the opportunity to help lead what could become the most impactful health initiative of our time,' she added. In a statement, eMed said Yaccarino's experience would be 'instrumental' as the company looks to expand its services to accommodate more 'national and global employer and government partnerships.' Yaccarino left X in July after two years as CEO, a day after the company's AI chatbot Grok declared itself 'MechaHitler' and repeatedly sexually harassed Yaccarino. It's unclear if her exit was directly connected to Grok's outbursts but the company later apologized, blaming a system update. Her time with X was filled up upheaval as Musk caused one controversy after another, leading to an exodus of advertisers. Yaccarino previously served as NBCUniversal Media's chair of global advertising and partnerships. eMed was launched in 2020, offering COVID-19 tests and services before pivoting to weight-loss drugs.
Yahoo
2 hours ago
- Yahoo
Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook
Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the consensus of $80.354 billion. Sales increased due to an 8.5% increase in revenue within the U.S. Healthcare Solutions segment and a 10.5% increase in revenue within the International Healthcare Solutions segment. 'Cencora delivered strong financial results in the third fiscal quarter, driven by our pharmaceutical-centric strategy and focus on our growth priorities,' said Robert Mauch, President and CEO of Cencora.U.S. Healthcare Solutions revenue was $72.9 billion in the third quarter of fiscal 2025, up 8.5% due to overall market growth primarily driven by unit volume growth, including increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class and specialty products to physician practices and health systems. International Healthcare Solutions' revenue was $7.8 billion. The company reported adjusted earnings of $4.00, up 19.8% year over year, beating the consensus of $3.82. Adjusted gross profit reached $2.9 billion, up 20.7%, and adjusted operating income was $1.1 billion, up 20.6%. Outlook Cencora updated its fiscal year 2025 financial guidance to reflect stronger earnings growth in the U.S. Healthcare Solutions segment. Cencora expects adjusted earnings to be $15.85-$16.00 versus prior guidance from $15.70-$15.95 and a consensus of $15.81. View more earnings on COR The company updated its fiscal 2025 sales guidance from $317.37 billion-$323.25 billion to approximately $320.31 billion compared to the consensus of $321.64 billion. The guidance assumes revenue growth of approximately 9% from the previous range of 8%-10%. U.S. Healthcare Solutions segment revenue growth is projected between 9%-10%, compared to the previous range of 9%-11%. International Healthcare Solutions segment revenue growth is projected to be in the range of 6%-7% from the previous range of 3% to 4%. Adjusted consolidated operating income growth to be between 15%-16%, from the previous range of 13.5%-15.5%. During the earnings conference call, Cencora said it's too early to assess the impact of Most Favored Nation (MFN) and other policy changes. Cencora's business has not been significantly affected by tariffs, and the company is not changing its sourcing practices as a result. The company remains confident in the stability of its supply chain. The company is monitoring differences in brand versus generic supply chains for risk of shortages and patient access disruptions. Price Action: Cencora stock is trading lower by 2.30% to $285.64 at last check Wednesday. Read Next:Photo by JHVEPhoto via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? CENCORA (COR): Free Stock Analysis Report This article Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤